FORM 3
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number: 3235-0104
Expires: February 28, 2011
Estimated average burden hours per response... 0.5

(Print or Type Responses)
1. Name and Address of Reporting Person *
  Burshtein Gregory
2. Date of Event Requiring Statement (Month/Day/Year)
05/28/2024		 3. Issuer Name and Ticker or Trading Symbol
Entera Bio Ltd. [ENTX]
(Last)
(First)
(Middle)
KIRYAT HADASSAH, MINRAV BUILDING,, FIFTH FLOOR		 4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
_____ Director _____ 10% Owner
__X__ Officer (give title below) _____ Other (specify below)
Chief of R&D
5. If Amendment, Date Original Filed (Month/Day/Year)
(Street)

JERUSALEM, L3 9112002		 6. Individual or Joint/Group Filing (Check Applicable Line)
_X_ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person
(City)
(State)
(Zip)
Table I - Non-Derivative Securities Beneficially Owned
1.Title of Security
(Instr. 4) 		2. Amount of Securities Beneficially Owned
(Instr. 4) 		3. Ownership Form: Direct (D) or Indirect (I)
(Instr. 5) 		4. Nature of Indirect Beneficial Ownership
(Instr. 5)
Ordinary Shares, par value NIS 0.0000769 per share 75,126 (1)
D
 

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. SEC 1473 (7-02)
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security
(Instr. 4) 		2. Date Exercisable and Expiration Date
(Month/Day/Year) 		3. Title and Amount of Securities Underlying Derivative Security
(Instr. 4) 		4. Conversion or Exercise Price of Derivative Security 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I)
(Instr. 5) 		6. Nature of Indirect Beneficial Ownership
(Instr. 5)
Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy)   (2) 01/17/2029 Ordinary Shares, par value NIS 0.0000769 per share 20,000 $ 3.97 D  
Stock Option (right to buy)   (3) 03/16/2030 Ordinary Shares, par value NIS 0.0000769 per share 18,900 $ 2.14 D  
Stock Option (right to buy)   (4) 04/07/2031 Ordinary Shares, par value NIS 0.0000769 per share 51,000 $ 3.61 D  
Stock Option (right to buy)   (5) 04/28/2032 Ordinary Shares, par value NIS 0.0000769 per share 45,000 $ 2.57 D  
Stock Option (right to buy)   (6) 03/24/2033 Ordinary Shares, par value NIS 0.0000769 per share 65,000 $ 0.795 D  
Stock Option (right to buy)   (7) 04/19/2034 Ordinary Shares, par value NIS 0.0000769 per share 150,000 $ 1.99 D  

Reporting Owners

Reporting Owner Name / Address Relationships
Director 10% Owner Officer Other
Burshtein Gregory
KIRYAT HADASSAH, MINRAV BUILDING,
FIFTH FLOOR
JERUSALEM, L3 9112002		       Chief of R&D  

Signatures

/s/ Dana Yaacov-Garbeli, Attorney-in-fact 06/07/2024
**Signature of Reporting Person Date

Explanation of Responses:

* If the form is filed by more than one reporting person, see Instruction 5(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
(1) Includes a grant of 25,126 stock-settled restricted stock units. The restricted stock units vest ratably on a quarterly basis over a one-year period that began on April 19, 2024.
(2) The options vest over a four-year period that commenced on January 17, 2019, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period.
(3) The options vest over a four-year period that commenced on March 16, 2020, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period.
(4) The options vest over a four-year period that commenced on April 7, 2021, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period.
(5) The options vest over a four-year period that commenced on April 28, 2022, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period.
(6) The options vest over a four-year period that commenced on April 24, 2023, with 25% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining three-year period.
(7) The options vest over a three-year period that commenced on April 19, 2024, with 33% of the options vesting on the first anniversary of the vesting commencement date. The remaining options vest ratably on a quarterly basis over the remaining two-year period.
 
Remarks:
See Exhibit 24.1 - Power of Attorney

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, See Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.